The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping

被引:48
|
作者
Weiss, M [1 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle, Germany
来源
关键词
fractal kinetics; tissue trapping; anomalous diffusion; recirculatory model; amiodarone;
D O I
10.1023/A:1020965005254
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Conventional pharmacokinetic (PK) concepts fail to describe the long-term pharmacokinetics of the extremely cationic amphiphilic drug amiodarone. A nonclassical model based on the phenomenon of trapping at tissue binding sites with very long release times is presented, which implies that a volume of distribution and a steady-state level cannot be defined. In a agreement with clinical PK data available in the literature, the model well deserves not only single-dose disposition curves but also the persistently increasing plasma concentration-time curve during long-term treatment (up to 5 years) and the washout curve following cessation of therapy. The novel aspect is a long-tailed tissue residence time distribution which is incorporated into a recirculatory model leaving the initial distribution process and the clearance concept unchanged. The underlying theoretical approach, which is known as "strange or anomalous" kinetics in physical sciences, and the fractal scaling property of the model may enhance our understanding of the PK of extremely hydrophobic xenobiotics.
引用
收藏
页码:383 / 396
页数:14
相关论文
共 50 条
  • [1] The Anomalous Pharmacokinetics of Amiodarone Explained by Nonexponential Tissue Trapping
    Michael Weiss
    Journal of Pharmacokinetics and Biopharmaceutics, 1999, 27 : 383 - 396
  • [2] Modeling the anomalous pharmacokinetics of amiodarone.
    Weiss, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 180 - 180
  • [3] THE EFFECT OF PHENOBARBITAL ON THE PHARMACOKINETICS AND TISSUE-LEVELS OF AMIODARONE
    FRUNCILLO, RJ
    BERNHARD, R
    SWANSON, BN
    VLASSES, PH
    FERGUSON, RK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (02) : 241 - 241
  • [4] AMIODARONE PHARMACOKINETICS
    HOLT, DW
    STOREY, GCA
    JACKSON, PR
    TUCKER, GT
    MCKENNA, WJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (02) : P206 - P206
  • [5] EFFECT OF PHENOBARBITONE ON THE PHARMACOKINETICS AND TISSUE-LEVELS OF AMIODARONE IN THE RAT
    FRUNCILLO, RJ
    BERNHARD, R
    SWANSON, BN
    VLASSES, PH
    FERGUSON, RK
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1985, 37 (10) : 729 - 731
  • [6] AMIODARONE PHARMACOKINETICS
    HOLT, DW
    TUCKER, GT
    JACKSON, PR
    STOREY, GCA
    AMERICAN HEART JOURNAL, 1983, 106 (04) : 840 - 847
  • [7] AMIODARONE PHARMACOKINETICS
    HOLT, DW
    TUCKER, GT
    JACKSON, PR
    MCKENNA, WJ
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1986, 40 (04): : 109 - 114
  • [8] CLINICAL PHARMACOKINETICS OF AMIODARONE
    LATINI, R
    TOGNONI, G
    KATES, RE
    CLINICAL PHARMACOKINETICS, 1984, 9 (02) : 136 - 156
  • [9] PHARMACOKINETICS OF AMIODARONE IN RATS
    RIVA, E
    GERNA, M
    NEYROZ, P
    URSO, R
    BARTOSEK, I
    GUAITANI, A
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (02) : 270 - 275
  • [10] PHARMACOLOGY AND PHARMACOKINETICS OF AMIODARONE
    FREEDMAN, MD
    SOMBERG, JC
    JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (11): : 1061 - 1069